Study ID | Malaria drug | HIV drug | Day | Statistics | PLHIV | HIV-uninfected group | Comparison | P-value | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Estimate | N | Estimate | N | Statistics | Estimate (95%CI) | Â | |||||
7 | AL or DP | TS | 1 | Percentage positive | 58.3 |  | 60.5 |  | RR | 0.97 (0.72–1.31) | 0.84 |
 | AL or DP | TS | 2 | Percentage positive | 19.4 |  | 5.0 |  | RR | 3.87 (1.85–8.12) |  < 0.001 |
9 | AL | EFV or NVP | 2 | N (%) positive | 9 (5.3) | 171 | Â | Â | Â | Â | Â |
 | AL | LPV/r | 2 | N (%) positive | 9 (8.4) | 107 |  |  |  |  |  |
 | AL | EFV or NVP | 3 | N (%) positive | 2 (1.2) | 171 |  |  |  |  |  |
 | AL | LPV/r | 3 | N (%) positive | 2 (1.9) | 105 |  |  |  |  |  |
11 | AL | EFV or NVP or LPV/r | 3 | Median (IQR) HL(h) | 3.51 (2.98–4.03) | 22 | 2.8 (2.38–3.36) | 77 |  |  | 0.003 |
12 | AL or SP | None | 3 | N/A | Â | N/A | Â | N/A | OR | 1.15 | 0.6 |
17 | AL | EFV | N/A | Median (range) PC50 (h) | 5.7 (0.3–25.8)a | 57 |  |  |  |  |  |
 | AL | EFV | N/A | Median (range) PC90 (h) | 13.8 (2.9–32.9)a | 57 |  |  |  |  |  |
18 | DP | EFV | N/A | Median (range) PC50 (h) | 4.2 (0.6–40.3) | 84 |  |  |  |  |  |
 | DP | EFV | N/A | Median (range) PC90 (h) | 10.1 (3.2–63.1) | 84 |  |  |  |  |  |
 | DP | EFV | N/A | Median (range) HL (h) | 2.2 (1.2–9.8) | 84 |  |  |  |  |  |
 | DP | EFV | N/A | N (%) HL > 5.5 h | 5 (6.0%) | 84 |  |  |  |  |  |
 | DP | NVP | N/A | Median (range) PC50 (h) | 3.1 (0.2–10.3) | 46 |  |  |  |  |  |
 | DP | NVP | N/A | Median (range) PC90 (h) | 8.2 (2.4–19.7) | 46 |  |  |  |  |  |
 | DP | NVP | N/A | Median (range) HL (h) | 2.1 (1.1–6.8) | 46 |  |  |  |  |  |
 | DP | NVP | N/A | N (%) HL > 5.5 h | 1 (2.2%) | 46 |  |  |  |  |  |
19b | AL | NVP, EFV | 3 | N (%) positive | 8 (11.8) | 68 | 12 (12.1) | 99 | Â | Â | 0.944 |